Please ensure Javascript is enabled for purposes of website accessibility

Why Achillion Pharmaceuticals, Inc. Stock Spiked Today

By George Budwell - Updated Feb 26, 2018 at 6:15PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Achillion got an important nod from European regulators today for its lead product candidate.

What happened

Shares of clinical-stage biotech Achillion Pharmaceuticals (ACHN) gained a healthy 15.4% today on around three times the average daily volume. What's going on? 

The company reported before the opening bell that the European Medicines Agency Committee for Orphan Medicinal Products issued a positive opinion on ACH-4471 for orphan status as a potential treatment for the rare kidney disorder known as C3 glomerulopathy, (C3G).

ACH-4471 is the company's lead product candidate. The drug is currently being assessed as a potential disease-modifying therapy in C3G, paroxysmal nocturnal hemoglobinuria, and immune complex-mediated membranoroliferative glomerulonephritis.

A person's hand holding up a vial containing a molecule of DNA.

Image source: Getty Images.

So what

The big-ticket item is that orphan-drug designation in the EU comes with a whopping 10-year period of marketing exclusivity after approval. So, if approved, Achillion's shares would probably garner a noteworthy premium because of the drug's rather lengthy period of exclusivity in key markets abroad. 

Now what

One of the most interesting aspects about Achillion is that it's exceptionally well capitalized for a company of its size and developmental state, thanks to its former hep C collaboration with Johnson & Johnson. Specifically, the biotech reported having a noteworthy $330 million in cash and cash equivalents earlier this month. That's a big deal, because it should translate into minimal dilution for shareholders as Achillion's early- to mid-stage pipeline for rare kidney ailments matures. 

Is Achillion worth buying right now? While some analysts have pegged ACH-4471 as a potential blockbuster if it can strike gold in multiple indications, this company is still a long way from filing a regulatory application. As such, Achillion is arguably a worthwhile watchlist candidate at this juncture, but not quite a screaming buy.   

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Achillion Pharmaceuticals, Inc. Stock Quote
Achillion Pharmaceuticals, Inc.
Johnson & Johnson Stock Quote
Johnson & Johnson
$179.52 (1.13%) $2.01

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/02/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.